Member Contact: Malcolm Hebblewhite
Industry: Medtech & Digital
Atmo Biosciences is a clinical stage digital health business focussed on providing objective real-time insights into gut health and microbiome function. Atmo’s world-first ingestible gas-sensing capsule measures clinically important gaseous biomarkers in real time at the source of production, and transmits the data wirelessly to the cloud for aggregation and analysis. Atmo addresses the need to monitor microbiome function, allowing improved diagnosis and personalised therapeutic approaches, resulting in earlier and more successful relief of symptoms, and reduced healthcare costs. The IP originated at RMIT University and Alfred Health, and was incubated by Planet Innovation before being spun out into a startup in 2018.